Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: GLS001
MIFTS: 54

Gliosarcoma

Categories: Bone diseases, Cancer diseases, Neuronal diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Gliosarcoma

About this section

MalaCards integrated aliases for Gliosarcoma:

Name: Gliosarcoma 12 74 52 58 54 43 15 17 71
Glioblastoma with Sarcomatous Component 12
Sarcomatous Glioblastoma 52

Characteristics:

Orphanet epidemiological data:

58
gliosarcoma
Inheritance: Not applicable; Age of onset: Adult;

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Neuronal diseases Bone diseases
See all MalaCards categories (disease lists)
ICD10: 33
Orphanet: 58  
Rare neurological diseases


External Ids:

Disease Ontology 12 DOID:3071
MeSH 43 D018316
NCIt 49 C3796
SNOMED-CT 67 35262004
ICD10 via Orphanet 33 C71.9
UMLS via Orphanet 72 C0206726
Orphanet 58 ORPHA251576
UMLS 71 C0206726
Sources

Summaries for Gliosarcoma

About this section
MalaCards based summary : Gliosarcoma, also known as glioblastoma with sarcomatous component, is related to glioblastoma multiforme and glial tumor, and has symptoms including seizures and headache. An important gene associated with Gliosarcoma is EGFR (Epidermal Growth Factor Receptor), and among its related pathways/superpathways are Apoptotic Pathways in Synovial Fibroblasts and Phospholipase-C Pathway. The drugs Trioxsalen and Donepezil have been mentioned in the context of this disorder. Affiliated tissues include brain, t cells and spinal cord, and related phenotypes are growth/size/body region and homeostasis/metabolism

Wikipedia : 74 Gliosarcoma is a rare type of glioma, a cancer of the brain that comes from glial, or supportive, brain... more...

Sources

Related Diseases for Gliosarcoma

About this section

Diseases related to Gliosarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 285)
# Related Disease Score Top Affiliating Genes
1 glioblastoma multiforme 32.3 TP53 PTEN PPARG NFKBIA NES MMP9
2 glial tumor 32.1 PTEN MMP9 IDH1
3 meningioma, familial 31.8 TP53 PTEN MGMT IDH1 GFAP EGFR
4 glioma 31.8 TP53 PTEN PPARG MMP9 MMP2 IDH1
5 malignant glioma 31.7 TP53 PTEN MMP9 MMP2 MGMT GFAP
6 benign ependymoma 31.6 NES MGMT GFAP EGFR
7 central nervous system cancer 31.5 TP53 PTEN NES MGMT IDH1 GFAP
8 oligodendroglioma 31.5 TP53 PTEN MGMT IDH1 GFAP FGFR1
9 fibrillary astrocytoma 31.5 TP53 PTEN MGMT IDH1 GFAP EGFR
10 grade iii astrocytoma 31.4 TP53 PTEN NES MMP9 MMP2 MGMT
11 teratoma 31.3 TP53 PTEN NES GFAP FGFR3
12 mixed glioma 31.3 TP53 PTEN NES MGMT IDH1 GFAP
13 oligoastrocytoma 31.3 MGMT GFAP
14 ganglioglioma 31.2 TP53 NES IDH1 GFAP
15 glioma susceptibility 1 31.2 TP53 PTEN PPARG NES MMP2 MGMT
16 brain cancer 31.2 TP53 PTEN NES MGMT IDH1 GFAP
17 neurofibroma 31.2 TP53 PTEN EGFR
18 hydrocephalus 31.1 TP53 PTEN NES GFAP FGFR3 FGFR1
19 adenoid cystic carcinoma 31.1 TP53 PTEN MMP9 MMP2 IDH1 EGFR
20 anaplastic ganglioglioma 31.1 NES GFAP
21 medulloblastoma 31.0 TP53 PTEN NES MMP9 MGMT IDH1
22 pleomorphic xanthoastrocytoma 31.0 TP53 MGMT IDH1 GFAP
23 arteriovenous malformation 31.0 PTEN MMP9 MMP2
24 carcinosarcoma 31.0 TP53 PTEN EGFR
25 juvenile pilocytic astrocytoma 31.0 PTEN NES MGMT IDH1 GFAP
26 thymus lymphoma 31.0 TP53 TACC3
27 li-fraumeni syndrome 30.9 TP53 PTEN IDH1 EGFR
28 neurilemmoma 30.9 NES LZTR1 GFAP
29 giant cell glioblastoma 30.9 TP53 TACC3 TACC1 SEPTIN14 PTEN PPARG
30 pancreatic cancer 30.7 TP53 PTEN PPARG NFKBIA NES MMP9
31 adult brainstem gliosarcoma 12.3
32 central nervous system primitive neuroectodermal neoplasm 10.8 TP53 NES GFAP
33 central nervous system immature teratoma 10.8 NES GFAP
34 extracranial arteriovenous malformation 10.8 MMP9 MMP2
35 bone squamous cell carcinoma 10.8 TP53 MMP9 EGFR
36 focal myositis 10.8 MMP9 MMP2
37 cerebellum cancer 10.8 TP53 IDH1 GFAP
38 extraventricular neurocytoma 10.8 IDH1 GFAP
39 splenic diffuse red pulp small b-cell lymphoma 10.8 TP53 CCND3
40 childhood brain stem glioma 10.8 TP53 MGMT IDH1
41 astroblastoma 10.8 NES IDH1 GFAP
42 colorectal adenoma 10.8 TP53 MMP9 MGMT EGFR
43 frontal lobe neoplasm 10.8 TP53 MGMT IDH1 EGFR
44 oral cancer 10.8 TP53 MMP9 MMP2 EGFR
45 oral submucous fibrosis 10.8 TP53 MMP9 MMP2
46 brain stem cancer 10.8 TP53 MGMT IDH1 EGFR
47 fgfr craniosynostosis syndromes 10.8 FGFR3 FGFR1
48 cheilitis 10.8 TP53 MMP9 FGFR3
49 lentigo maligna melanoma 10.8 MMP9 MMP2
50 osteochondroma 10.8 NES FGFR3 FGFR1

Graphical network of the top 20 diseases related to Gliosarcoma:



Diseases related to Gliosarcoma
Sources

Symptoms & Phenotypes for Gliosarcoma

About this section

UMLS symptoms related to Gliosarcoma:


seizures, headache

MGI Mouse Phenotypes related to Gliosarcoma:

45 (show all 20)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.43 CCND3 EGFR FGFR1 FGFR3 FREM2 GFAP
2 homeostasis/metabolism MP:0005376 10.37 CCND3 EGFR FGFR1 FGFR3 GFAP IDH1
3 mortality/aging MP:0010768 10.36 CCND3 EGFR FGFR1 FGFR3 FREM2 GFAP
4 hematopoietic system MP:0005397 10.35 CCND3 EGFR FGFR1 FGFR3 IDH1 LZTR1
5 cardiovascular system MP:0005385 10.33 CCND3 EGFR FGFR1 FREM2 GFAP LZTR1
6 cellular MP:0005384 10.32 EGFR FGFR1 FGFR3 GFAP LZTR1 MMP9
7 immune system MP:0005387 10.32 CCND3 EGFR FGFR1 FGFR3 GFAP IDH1
8 endocrine/exocrine gland MP:0005379 10.22 CCND3 EGFR FGFR1 MGMT NFKBIA PPARG
9 craniofacial MP:0005382 10.18 EGFR FGFR1 FGFR3 FREM2 LZTR1 MMP2
10 integument MP:0010771 10.15 EGFR FGFR1 FGFR3 FREM2 MMP9 NFKBIA
11 muscle MP:0005369 10.13 EGFR FGFR1 FREM2 GFAP LZTR1 MMP2
12 nervous system MP:0003631 10.11 EGFR FGFR1 FGFR3 FREM2 GFAP MGMT
13 neoplasm MP:0002006 10.1 CCND3 EGFR FGFR3 MGMT MMP2 MMP9
14 limbs/digits/tail MP:0005371 10.08 EGFR FGFR1 FGFR3 FREM2 MMP9 PTEN
15 normal MP:0002873 10.06 CCND3 EGFR FGFR1 FGFR3 GFAP MMP2
16 hearing/vestibular/ear MP:0005377 10.02 EGFR FGFR1 FGFR3 FREM2 PPARG TP53
17 renal/urinary system MP:0005367 9.86 EGFR FGFR1 FGFR3 FREM2 MMP9 PPARG
18 respiratory system MP:0005388 9.85 CCND3 EGFR FGFR3 FREM2 IDH1 MGMT
19 skeleton MP:0005390 9.73 EGFR FGFR1 FGFR3 FREM2 IDH1 LZTR1
20 vision/eye MP:0005391 9.36 CCND3 EGFR FGFR1 FGFR3 FREM2 GFAP
Sources

Drugs & Therapeutics for Gliosarcoma

About this section

Drugs for Gliosarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 372)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Trioxsalen Approved Phase 3 3902-71-4 5585
2
Donepezil Approved Phase 3 120014-06-4 3152
3
Leflunomide Approved, Investigational Phase 3 75706-12-6 3899
4
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
5
Ipilimumab Approved Phase 2, Phase 3 477202-00-9
6
Bevacizumab Approved, Investigational Phase 3 216974-75-3
7
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
8
Carboplatin Approved Phase 3 41575-94-4 10339178 38904 498142
9
Histamine Approved, Investigational Phase 3 51-45-6 774
10
Cyproheptadine Approved Phase 3 129-03-3 2913
11
Lomustine Approved, Investigational Phase 3 13010-47-4 3950
12
Methylphenidate Approved, Investigational Phase 3 113-45-1 4158
13
Rindopepimut Investigational Phase 3 1108208-65-6
14 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
15
Veliparib Investigational Phase 2, Phase 3 912444-00-9 11960529
16 Dianhydrogalactitol Investigational Phase 3 23261-20-3
17 Endothelial Growth Factors Phase 3
18 Photosensitizing Agents Phase 3
19 Immunoglobulin G Phase 3
20 Analgesics Phase 3
21 Anesthetics Phase 3
22 Dihematoporphyrin Ether Phase 3
23 Hematoporphyrins Phase 3
24 Anesthetics, General Phase 3
25 Hematoporphyrin Derivative Phase 3
26 Ether Phase 3
27 Anesthetics, Inhalation Phase 3
28 Liver Extracts Phase 3
29 Cholinesterase Inhibitors Phase 3
30 Cholinergic Agents Phase 3
31 Cola Phase 3
32 Narcotics Phase 3
33 Analgesics, Opioid Phase 3
34 Anesthetics, Intravenous Phase 3
35 Mitogens Phase 2, Phase 3
36 Immunoconjugates Phase 2, Phase 3
37 Poly(ADP-ribose) Polymerase Inhibitors Phase 2, Phase 3
38 Neurotransmitter Agents Phase 3
39 Dopamine Agents Phase 3
40 Gastrointestinal Agents Phase 3
41 Histamine Antagonists Phase 3
42 Anti-Allergic Agents Phase 3
43
Histamine Phosphate Phase 3 51-74-1 65513
44 Histamine H1 Antagonists Phase 3
45 Central Nervous System Stimulants Phase 3
46 Dexmethylphenidate Hydrochloride Phase 3
47
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
48
Ethanol Approved Phase 2 64-17-5 702
49
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
50
Etoposide Approved Phase 2 33419-42-0 36462

Interventional clinical trials:

(show top 50) (show all 494)
# Name Status NCT ID Phase Drugs
1 Prospective Clinical Trials in the Use of Photodynamic Therapy (PDT) for the Treatment of Malignant Supratentorial Brain Tumors Unknown status NCT00003788 Phase 3 carmustine;lomustine;porfimer sodium;procarbazine hydrochloride
2 A Phase III Study of Radiation Therapy (RT) and O6-Benzylguanine (O6-BG) Plus BCNU Versus RT and BCNU Alone for Newly Diagnosed Glioblastoma Multiforme (GBM) and Gliosarcoma Completed NCT00017147 Phase 3 carmustine;O6-Benzylguanine
3 Phase III Trial Comparing Conventional Adjuvant Temozolomide With Dose-Intensive Temozolomide in Patients With Newly Diagnosed Glioblastoma Completed NCT00304031 Phase 3 Concurrent temozolomide;100mg/m2 adjuvant temozolomide days 1 to 5 of 28 day cycle;75mg/m2 adjuvant temozolomide days 1-21 of 28 day cycle
4 An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF With Adjuvant Temozolomide in Patients With Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma Completed NCT01480479 Phase 3 Rindopepimut (CDX-110) with GM-CSF;Temozolomide;KLH
5 A PHASE III TRIAL COMPARING THE USE OF RADIOSURGERY FOLLOWED BY CONVENTIONAL RADIOTHERAPY WITH BCNU TO CONVENTIONAL RADIOTHERAPY WITH BCNU FOR SUPRATENTORIAL GLIOBLASTOMA MULTIFORME Completed NCT00002545 Phase 3 carmustine
6 Randomized Study of Normal-fractionated Radiotherapy Versus Hypofractionated Radiotherapy Versus Chemotherapy in Patients Over 60 Years With Malignant Glioma Completed NCT00820963 Phase 3 temozolomide
7 Focal Fractionated Conformal Stereotactic Boost Following Conventional Radiotherapy of High Grade Gliomas: A Randomized Phase III Study Completed NCT00003916 Phase 3
8 A Randomized Prospective Two Arm Clinical Trial of High Light Dose And Low Light Dose PDT in the Treatment of Recurrent Malignant Supratentorial Gliomas Using Porfimer Sodium [Photofrin] Completed NCT00118222 Phase 3 porfimer sodium
9 Phase III Double-blind Placebo-Controlled Trial of Conventional Concurrent Chemoradiation and Adjuvant Temozolomide Plus Bevacizumab Versus Conventional Concurrent Chemoradiation and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma Completed NCT00884741 Phase 3 Temozolomide
10 Phase III Double Blind, Placebo Controlled Study of Donepezil in the Irradiated Brain Completed NCT00369785 Phase 3 donepezil hydrochloride;Placebo
11 Concomitant and Adjuvant Temozolomide and Radiotherapy for Newly Diagnosed Glioblastoma Multiforme - A Randomized Phase III Study Completed NCT00006353 Phase 3 temozolomide
12 A Phase III Randomized Study of SU101 Versus Procarbazine for Patients With Glioblastoma Multiforme in First Relapse Completed NCT00003293 Phase 3 leflunomide;procarbazine hydrochloride
13 A Prospective Randomised Trial Comparing Temozolomide With PCV In The Treatment Of Recurrent WHO Astrocytic Tumours Grades III And IV Completed NCT00052455 Phase 3 lomustine;procarbazine hydrochloride;temozolomide;vincristine sulfate
14 A Randomized Phase III Study of Temozolomide and Short-Course Radiation Versus Short-Course Radiation Alone In The Treatment of Newly Diagnosed Glioblastoma Multiforme in Elderly Patients Completed NCT00482677 Phase 3 temozolomide
15 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
16 A Randomized, Placebo Controlled Phase 3 Study of ABT-414 With Concurrent Chemoradiation and Adjuvant Temozolomide in Subjects With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification (Intellance1) Active, not recruiting NCT02573324 Phase 2, Phase 3 Temozolomide;ABT-414;Placebo for ABT-414
17 A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation Active, not recruiting NCT02152982 Phase 2, Phase 3 Temozolomide;Veliparib
18 A Randomized Phase II/III Open-Label Study of Ipilimumab and Nivolumab Versus Temozolomide in Patients With Newly Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated Glioblastoma Not yet recruiting NCT04396860 Phase 2, Phase 3 Temozolomide
19 Prevention of Cancer/Treatment-Related Weight Loss in Children at High Nutritional Risk Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
20 A Phase III, Double-Blind, Prospective Randomized Clinical Trial of the Effect of D-threo-methylphenidate HCl (d-MPH) on Quality of Life in Brain Tumor Patients Receiving Radiation Therapy Terminated NCT00031798 Phase 3 methylphenidate hydrochloride
21 A Pivotal Randomized, Controlled Trial of VAL-083 in Patients With Recurrent Glioblastoma Who Have Failed Standard Temozolomide/Radiation Therapy and Bevacizumab (STAR-3) Terminated NCT03149575 Phase 3 VAL-083, Dianhydrogalactitol;Physician's Choice of Salvage Therapy - temozolomide;Physician's Choice of Salvage Therapy - lomustine;Physician's Choice of Salvage Therapy - carboplatin
22 A Randomized Phase III Study of Re-Irradiation in Recurrent Glioblastoma Withdrawn NCT01830101 Phase 3 TMZ plus concurrent re-irradiation;Temozolomide
23 Phase III Randomized Evaluation of 13-Cis-Retinoic Acid (cRA) Plus Procarbazine Versus Procarbazine Alone in the Treatment of Patients With Recurrent Primary Malignant Gliomas Withdrawn NCT00003564 Phase 3 Isotretinoin;Procarbazine Hydrochloride
24 A Phase 2 Study of AR-67 (7-t-butyldimethylsiltyl-10-hydroxy-camptothecin) in Adult Patients With Recurrence of Glioblastoma Multiforme (GBM) or Gliosarcoma Unknown status NCT01124539 Phase 2 AR-67 (7-t-butyldimethylsiltyl-10-hydroxy-camptothecin)
25 Phase IIb Trial Evaluations Of The Effectiveness Of Treatment Glioblastoma / Gliosarcoma Through The Suppression Of The PI3K/Akt Pathway In Compared With MK-3475 (Pembrolizumab) Unknown status NCT02430363 Phase 1, Phase 2 MK - 3475
26 Phase II Trial of Bevacizumab in Combination With Temozolomide and Regional Radiation Therapy for Upfront Treatment of Patients With Newly-diagnosed Glioblastoma Multiforme Unknown status NCT01013285 Phase 2 temozolomide
27 Phase II Study Trial Of Tarceva In Patients With Recurrent/Progressive Glioblastoma Multiforme Unknown status NCT00054496 Phase 2 erlotinib hydrochloride
28 A Phase II Open-Label, Multiple-Dose Study of Intracavitary Administered 131-I-TM-601 in Adult Patients With Recurrent High-Grade Glioma Unknown status NCT00114309 Phase 2 131-I-TM-601;131I-TM601
29 Phase I/II Clinical Trial of the Safety, Tolerability, and Anti-tumor Efficacy of the IGF-1R Inhibitor, AXL1717 (Picropodophyllin), in the Treatment of Recurrent Malignant Astrocytomas Unknown status NCT01721577 Phase 1, Phase 2 AXL1717
30 A Phase I/II Trial of Conformal Radiotherapy and Hyperbaric Oxygen for Patients With Newly Diagnosed Glioblastoma Unknown status NCT00006460 Phase 1, Phase 2 hyperbaric oxygen
31 A Phase 2 Study of Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Malignant Glial Tumors of the Brain Unknown status NCT01403311 Phase 2 5-Aminolevuline Acid
32 A Phase I/II Study of the Safety and Tolerability of DTI-015 in Patients With Recurrent Glioblastoma Multiforme Unknown status NCT00006656 Phase 2 carmustine in ethanol
33 Phase I/II Study of Intratumoral Injection of DTI-015 Prior to Tumor Resection in Patients With Recurrent Malignant Glioma or Metastatic Neoplasm to Brain Unknown status NCT00009854 Phase 1, Phase 2 carmustine in ethanol
34 A Phase II Pilot Trial of Radiation Therapy With Concurrent and Adjuvant Temozolomide, Tamoxifen and Carboplatin (T2C) in the Treatment of Patients With Primary Central Nervous System Malignant Gliomas Unknown status NCT00492687 Phase 2 carboplatin;tamoxifen citrate;temozolomide
35 Phase I/II Trial of Temozolomide and Carboplatin in Recurrent Glioblastoma Multiforme Unknown status NCT00014105 Phase 1, Phase 2 carboplatin;temozolomide
36 Continuous Infusion Thiotepa in High Grade Astrocytic Tumors of Childhood and Adolescence A UKCCSG Phase II Study Involving the Brain Tumour and New Agent Groups Unknown status NCT00313521 Phase 2 thiotepa
37 Phase II Pilot Trial of Hyperbaric Hyperoxygenation in Conjunction With Radiotherapy and Temozolomide In Adults With Newly Diagnosed Glioblastomas Unknown status NCT00936052 Phase 2
38 A Phase II Study of Bevacizumab Plus Temodar and Tarceva After Radiation Therapy and Temodar in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma Who Are Stable Following Radiation Completed NCT00525525 Phase 2 Bevacizumab;Tarceva;Temozolomide
39 Phase II Study of Tarceva Plus Temodar During and Following Radiation Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme and Gliosarcoma Completed NCT00187486 Phase 2 Tarceva;Temodar
40 Phase II Study of Bi-Weekly Temozolomide Plus Bevacizumab for Adult Patients With Recurrent Glioblastoma Multiforme Completed NCT00883298 Phase 2 temozolomide and bevacizumab
41 Phase II Study to Evaluate the Efficacy and Safety of AMG 102 and Avastin in Subjects With Recurrent Malignant Glioma Completed NCT01113398 Phase 2 AMG 102;Avastin
42 Phase I/II Studies of BAY 43-9006 (Sorafenib) in Combination With OSI-774 (Erlotinib), R115777 (Tipifarnib) or CCI-779 (Temsirolimus) in Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma Completed NCT00335764 Phase 1, Phase 2 sorafenib tosylate;erlotinib hydrochloride;tipifarnib;temsirolimus
43 Phase II Study of Lenalidomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme. Completed NCT00165477 Phase 2 lenalidomide
44 Phase II Trial of Dasatinib in Patients With Recurrent Glioblastoma Multiforme Completed NCT00423735 Phase 2 Dasatinib
45 Phase 1/2 Study of Enzastaurin Plus Temozolomide During and Following Radiation Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma Completed NCT00402116 Phase 1, Phase 2 enzastaurin;temozolomide
46 A Phase I/II Study of the Combination of Indoximod and Temozolomide for Adult Patients With Temozolomide-Refractory Primary Malignant Brain Tumors Completed NCT02052648 Phase 1, Phase 2 Indoximod;Temozolomide;Bevacizumab
47 Avastin in Combination With Temozolomide and Irinotecan for Unresectable or Multifocal Glioblastoma Multiformes and Gliosarcomas Completed NCT00979017 Phase 2 Avastin;Temozolomide;Irinotecan
48 Phase II Evaluation of Temozolomide (SCH52365) and Thalidomide for the Treatment of Recurrent and Progressive Glioblastoma Multiforme Completed NCT00006358 Phase 2 temozolomide;thalidomide
49 Phase II Trial of BCNU Plus O6-Benzylguanine in the Treatment of Patients With Recurrent or Progressive Cerebral Anaplastic Gliomas Completed NCT00005081 Phase 2 O6-benzylguanine;carmustine
50 Phase II Trial of Velcade (Bortezomib) in Combination With Temozolomide and Regional Radiation Therapy for Upfront Treatment of Patients With Newly-diagnosed Glioblastoma Multiforme Completed NCT00998010 Phase 2 bortezomib + temozolomide+ radiation therapy

Search NIH Clinical Center for Gliosarcoma

Cochrane evidence based reviews: gliosarcoma

Sources

Genetic Tests for Gliosarcoma

About this section
Sources

Anatomical Context for Gliosarcoma

About this section

MalaCards organs/tissues related to Gliosarcoma:

40
Brain, T Cells, Spinal Cord, Bone, Prostate, Endothelial, Liver
Sources

Publications for Gliosarcoma

About this section

Articles related to Gliosarcoma:

(show top 50) (show all 1015)
# Title Authors PMID Year
1
Treatment of rat gliosarcoma brain tumors by HSV-based multigene therapy combined with radiosurgery. 61 54
14529825 2003
2
Characterisation of molecular alterations in microdissected archival gliomas. 54 61
11355303 2001
3
Positron emission tomography-based imaging of transgene expression mediated by replication-conditional, oncolytic herpes simplex virus type 1 mutant vectors in vivo. 54 61
11306477 2001
4
Genetic profile of gliosarcomas. 61 54
10666371 2000
5
Amplification and expression of cyclin D genes (CCND1, CCND2 and CCND3) in human malignant gliomas. 54 61
10416984 1999
6
Connexins are expressed in primary brain tumors and enhance the bystander effect in gene therapy. 61 54
9932890 1999
7
The effect of ganciclovir on herpes simplex virus-mediated oncolysis. 61 54
9224416 1997
8
Rapid detection of transferrin receptor expression on glioma cell lines by using magnetic microspheres. 54 61
8264887 1993
9
Gliosarcoma of the posterior fossa with features of a malignant fibrous histiocytoma. 61 54
2154322 1990
10
Toward personalized synchrotron microbeam radiation therapy. 61
32483249 2020
11
NRG/RTOG 1122: A phase 2, double-blinded, placebo-controlled study of bevacizumab with and without trebananib in patients with recurrent glioblastoma or gliosarcoma. 61
32154928 2020
12
Retrobulbar chlorpromazine injection in a child with gliosarcoma invasion into the orbits. 61
32522719 2020
13
Analysis of the effect of photodynamic therapy with Fotoenticine on gliosarcoma cells. 61
32050104 2020
14
Update on Circumscribed Gliomas and Glioneuronal Tumors. 61
32389265 2020
15
Spinal metastasis of glioblastoma multiforme before gliosarcomatous transformation: a case report. 61
32393192 2020
16
Neuroinflammation following stereotactic radiosurgery-induced brain tumor disintegration is linked to persistent cognitive decline in a mouse model of metastatic disease. 61
32470502 2020
17
Prognostic factors and clinical outcomes in adult primary gliosarcoma patients: a Surveillance, Epidemiology, and End Results (SEER) analysis from 2004 to 2015. 61
31829033 2020
18
Primary Gliosarcoma with Extracranial Metastasis. 61
32390354 2020
19
Clinical implications of multiple glioblastomas: An analysis of prognostic factors and survival to distinguish from their single counterparts. 61
31515159 2020
20
The clinical, radiological, and immunohistochemical characteristics and outcomes of primary intracranial gliosarcoma: a retrospective single-centre study. 61
32189095 2020
21
Gliosarcomas: magnetic resonance imaging findings. 61
32022137 2020
22
Molecular and clonal evolution in recurrent metastatic gliosarcoma. 61
31896544 2020
23
The Coexistence of Gliosarcoma and Arteriovenous Malformation with the BRAF V600E Mutation. 61
31759151 2020
24
Genetic and histologic spatiotemporal evolution of recurrent, multifocal, multicentric and metastatic glioblastoma. 61
32014051 2020
25
Primary pediatric cerebellar gliosarcoma. 61
32494375 2020
26
Gliosarcoma case report and review of the literature. 61
32341747 2020
27
Evaluating Surgical Resection Extent and Adjuvant Therapy in the Management of Gliosarcoma. 61
32219069 2020
28
99mTc-CXCR4-L for Imaging of the Chemokine-4 Receptor Associated with Brain Tumor Invasiveness: Biokinetics, Radiation Dosimetry, and Proof of Concept in Humans. 61
32410920 2020
29
Angiosarcomatous component in gliosarcoma: case report and consideration of diagnostic challenge and hemorrhagic propensity. 61
32305969 2019
30
Identification of Distant Metastases From Recurrent Gliosarcoma Using Whole-Body 18F-FDG PET/CT. 61
31584491 2019
31
Multi-layered core-sheath fiber membranes for controlled drug release in the local treatment of brain tumor. 61
31784666 2019
32
Impact of brain tumors and radiotherapy on the presence of gadolinium in the brain after repeated administration of gadolinium-based contrast agents: an experimental study in rats. 61
31297571 2019
33
Prognostic factors among single primary gliosarcoma cases: A study using Surveillance, Epidemiology, and End Results data from 1973-2013. 61
31464103 2019
34
Overall Survival in Malignant Glioma Is Significantly Prolonged by Neurosurgical Delivery of Etoposide and Temozolomide from a Thermo-Responsive Biodegradable Paste. 61
31113843 2019
35
Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1. 61
31399043 2019
36
Gliosarcoma: distinct molecular pathways and genomic alterations identified by DNA copy number/SNP microarray analysis. 61
31073965 2019
37
Prognosis and management of gliosarcoma patients: A review of literature. 61
31112812 2019
38
Clinical characteristics and disease-specific prognostic nomogram for primary gliosarcoma: a SEER population-based analysis. 61
31341246 2019
39
Cerebral gliosarcoma with perivascular involvement in a cat. 61
31636916 2019
40
Hybrid magneto-fluorescent nano-probe for live apoptotic cells monitoring at brain cerebral ischemia. 61
30948085 2019
41
Racial/ethnic differences in survival for patients with gliosarcoma: an analysis of the National cancer database. 61
30989622 2019
42
Gliosarcoma in a Young Filipino Woman: A Case Report and Review of the Literature. 61
31243260 2019
43
Xenografting for disease modeling of intramedullary spinal cord tumors: a systematic review. 61
30710121 2019
44
Longitudinal evaluation of tumor microenvironment in rat focal brainstem glioma using diffusion and perfusion MRI. 61
30318760 2019
45
Evaluating the Association Between the Extent of Resection and Survival in Gliosarcoma. 61
31218139 2019
46
Neuroglial Differentiation and Neoplasms in Testicular Germ Cell Tumors Lack Immunohistochemical Evidence of Alterations Characteristic of Their CNS Counterparts: A Study of 13 Cases. 61
30557172 2019
47
Gliosarcoma Is Driven by Alterations in PI3K/Akt, RAS/MAPK Pathways and Characterized by Collagen Gene Expression Signature. 61
30818875 2019
48
Extracranial metastases in glioblastoma-Two case stories. 61
30847191 2019
49
Biodegradable wafers releasing Temozolomide and Carmustine for the treatment of brain cancer. 61
30605703 2019
50
Primary Gliosarcoma of the Cerebellum in a Young Pregnant Woman: Management Challenges and Immunohistochemical Features. 61
31396432 2019
Sources

Variations for Gliosarcoma

About this section

Cosmic variations for Gliosarcoma:

9
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)		 Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM93246226 central nervous system,brain,glioma,gliosarcoma c.840A>T p.R280S 17:7673780-7673780 0
Sources

Expression for Gliosarcoma

About this section
Search GEO for disease gene expression data for Gliosarcoma.
Sources

Pathways for Gliosarcoma

About this section

Pathways related to Gliosarcoma according to GeneCards Suite gene sharing:

(show all 38)
# Super pathways Score Top Affiliating Genes
1
Apoptotic Pathways in Synovial Fibroblasts 63
Show member pathways
 13.8 TP53 PTEN PPARG NFKBIA MMP9 MMP2
2
Phospholipase-C Pathway 63
Show member pathways
 13.03 TP53 PTEN FREM2 FGFR3 FGFR1 EGFR
3
PI3K-Akt signaling pathway 36
Show member pathways
 12.95 TP53 PTEN FGFR3 FGFR1 EGFR CCND3
4
Downstream signaling events of B Cell Receptor (BCR) 65
Show member pathways
 12.64 TP53 PTEN NFKBIA FGFR3 FGFR1 EGFR
5
Endometrial cancer 36
Show member pathways
 12.61 TP53 PTEN PPARG NFKBIA MMP9 FGFR1
6
Glioma 36
Show member pathways
 12.53 TP53 PTEN MMP9 MMP2 FGFR1 EGFR
7
MicroRNAs in cancer 36
12.49 TP53 PTEN MMP9 FGFR3 EGFR
8
mTOR signaling pathway (KEGG) 36
Show member pathways
 12.45 TP53 PTEN FGFR3 FGFR1 EGFR
9
VEGF Signaling 66
Show member pathways
 12.44 TP53 PTEN FGFR3 FGFR1 EGFR
10
Apoptosis Pathway 70
Show member pathways
 12.36 TP53 NFKBIA FGFR3 FGFR1 EGFR
11
Development IGF-1 receptor signaling 22
Show member pathways
 12.35 TP53 PTEN NFKBIA CCND3
12
Human T-cell leukemia virus 1 infection 36
12.31 TP53 PTEN NFKBIA CCND3
13
Translation Non-genomic (rapid) action of Androgen Receptor 22
Show member pathways
 12.28 TP53 PTEN MMP2 EGFR
14
G-protein signaling Ras family GTPases in kinase cascades (scheme) 22
Show member pathways
 12.26 TP53 PPARG NFKBIA EGFR
15
Proteoglycans in cancer 36
12.2 TP53 MMP9 MMP2 FGFR1 EGFR
16
Colorectal Cancer Metastasis 63
12.15 TP53 MMP9 MMP2 EGFR
17
Pathways in cancer 36
12.05 TP53 PTEN PPARG NFKBIA MMP9 MMP2
18
MAPK Signaling: Mitogens 64
Show member pathways
 12.03 TP53 PTEN FGFR3 FGFR1 EGFR CCND3
19
Direct p53 effectors 1
12.01 TP53 PTEN MMP2 EGFR
20
Spinal Cord Injury 1
11.95 TP53 MMP9 GFAP EGFR
21
Glioblastoma Multiforme 63
11.89 TP53 PTEN MGMT EGFR
22
Small cell lung cancer 36
11.82 TP53 PTEN NFKBIA
23
Angiogenesis (CST) 4
11.76 MMP9 MMP2 FGFR3 FGFR1
24
Neural Stem Cells and Lineage-specific Markers 64
11.68 NES GFAP FGFR3 FGFR1
25
Endochondral Ossification 1
11.64 MMP9 FGFR3 FGFR1
26
Photodynamic therapy-induced NF-kB survival signaling 1
Show member pathways
 11.63 NFKBIA MMP9 MMP2
27
Cell adhesion_ECM remodeling 22
11.61 MMP9 MMP2 EGFR
28
IL-2 Gene Expression in Activated and Quiescent T-Cells 63
Show member pathways
 11.55 NFKBIA MMP9 MMP2 EGFR
29
AGE/RAGE pathway 1
11.55 NFKBIA MMP9 MMP2 EGFR
30
Photodynamic therapy-induced AP-1 survival signaling. 1
11.52 TP53 MMP2 EGFR
31
LPA receptor mediated events 1
11.52 NFKBIA MMP9 MMP2 EGFR
32
Osteopontin-mediated events 1
Show member pathways
 11.45 NFKBIA MMP9 MMP2
33
Alzheimers Disease Pathway 63
11.45 FGFR3 FGFR1 EGFR
34
DNA damage_ATM/ATR regulation of G1/S checkpoint 22
11.43 TP53 NFKBIA CCND3
35
Bladder cancer 36 1
11.42 TP53 MMP9 MMP2 FGFR3 EGFR
36
Vemurafenib Pathway, Pharmacodynamics 60
11.41 FGFR3 FGFR1 EGFR
37
Central carbon metabolism in cancer 36
11.28 TP53 PTEN IDH1 FGFR3 FGFR1 EGFR
38
Aurora A signaling 1
11.05 TP53 TACC3 TACC1 NFKBIA
Sources

GO Terms for Gliosarcoma

About this section

Cellular components related to Gliosarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 9.5 TP53 TACC3 TACC1 SEPTIN14 PTEN PPARG

Biological processes related to Gliosarcoma according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 heart development GO:0007507 9.78 TP53 PTEN PPARG FREM2
2 negative regulation of apoptotic process GO:0043066 9.63 TP53 PTEN NFKBIA MMP9 MGMT EGFR
3 positive regulation of kinase activity GO:0033674 9.54 FGFR3 FGFR1 EGFR
4 negative regulation of macrophage derived foam cell differentiation GO:0010745 9.49 PPARG NFKBIA
5 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.46 TP53 EGFR
6 negative regulation of telomerase activity GO:0051974 9.43 TP53 PPARG
7 cellular response to reactive oxygen species GO:0034614 9.43 MMP9 MMP2 EGFR
8 salivary gland morphogenesis GO:0007435 9.4 FGFR1 EGFR
9 regulation of cell proliferation GO:0042127 9.35 TP53 NFKBIA FGFR1 EGFR CCND3
10 positive regulation of phospholipase activity GO:0010518 9.32 FGFR3 FGFR1
11 response to organic cyclic compound GO:0014070 9.02 PTEN PPARG MGMT IDH1 EGFR

Molecular functions related to Gliosarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 enzyme binding GO:0019899 9.55 TP53 PTEN PPARG NFKBIA EGFR
2 protein phosphatase binding GO:0019903 9.5 TP53 PPARG EGFR
3 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.43 FGFR3 FGFR1 EGFR
4 identical protein binding GO:0042802 9.32 TP53 PTEN PPARG NFKBIA MMP9 IDH1
5 fibroblast growth factor-activated receptor activity GO:0005007 8.96 FGFR3 FGFR1
Sources

Sources for Gliosarcoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....